StockIQ.techMerck & Co. Inc. (MRK) Stock Analysis
Free AI-powered analysis and research for Merck & Co. Inc. stock
Sector: Healthcare
MRK snapshot
Data as of 3 Nov 2026 close. Updated daily.
Merck & Co. Inc. scores 51/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 84% of its 52-week range, up 75.4% over the past year. Latest reported figures show a profit margin of 3.6% and revenue growth of +4.7%.
What is driving the score
- RSI Neutral: +5
- Downtrend: -4
- MACD Bullish: +8
- High P/E (118.7): -10
- Weak Profit Margin (3.6%): -8
- High P/B (8.80): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+75.4% over 1 year): +10
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full MRK report
Merck & Co. Inc. (MRK) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze MRK Now →📰 Latest Update
Competent Cells - Global Strategic Business Report 2026: Secure Share of the $3.2 Billion Market by 2032 - Agilent, Bio-Rad, GenScript, and Merck Drive 9.2% CAGR
Tue, November 3, 2026 at 2:49 PM UTC 3 min read
The global competent cells market, valued at US$1.7 billion in 2025, is projected to reach US$3.2 billion by 2032, growing at a CAGR of 9.2%. Key drivers include rising demand for DNA transformation technologies in pharmaceutical and biotechnology sectors, with electrocompetent cells expected to grow at a 10.6% CAGR. The report highlights advancements in cell engineering and the increasing importance of specialized strains for various applications, including drug discovery and synthetic biology.